Abstract
Vascular smooth muscle cells (VSMCs) are indispensable components in foam cell formation in atherosclerosis. However, the mechanism behind foam cell formation of VSMCs has not been addressed. We found a potential association between deletion of smooth muscle (SM) 22α and deregulated nuclear receptors liver X receptors (LXRs)/retinoid X receptor (RXR) signaling in mice. Here, we investigated the roles of SM22α in LXRα-modulated cholesterol homeostasis, and explore possible mechanisms underlying this process. We identified that the depletion of SM22α was a primary event driving VSMC cholesterol accumulation and the development of atherosclerosis in mice. Proteomic and lipidomic analysis validated that downregulation of SM22α was correlated with reduced expression of LXRα and ATP-binding cassette transporter (ABCA) 1 and increased cholesteryl ester in phenotypically modulated VSMCs induced by platelets-derived growth factor (PDGF)-BB. Notably, LXRα was mainly distributed in the cytoplasm rather than the nucleus in the neointimal and Sm22α−/− VSMCs. Loss of SM22α inhibited the nuclear import of LXRα and reduced ABCA1-mediated cholesterol efflux via promoting depolymerization of actin stress fibers. Affinity purification and mass spectrometry (AP-MS) analysis, co-immunoprecipitation and GST pull-down assays, confocal microscopy, and stochastic optical reconstruction microscopy (STORM) revealed that globular-actin (G-actin), monomeric actin, interacted with and retained LXRα in the cytoplasm in PDGF-BB-treated and Sm22α−/− VSMCs. This interaction blocked LXRα binding to Importin α, a karyopherin that mediates the trafficking of macromolecules across the nuclear envelope, and the resulting reduction of LXRα transcriptional activity. Increasing SM22α expression restored nuclear localization of LXRα and removed cholesterol accumulation via inducing actin polymerization, ameliorating atherosclerosis. Our findings highlight that LXRα is a mechanosensitive nuclear receptor and that the nuclear import of LXRα maintained by the SM22α-actin axis is a potential target for blockade of VSMC foam cell formation and development of anti-atherosclerosis.
Subject terms: Lipoproteins, Actin, Proteomics, Atherosclerosis, Experimental models of disease
Introduction
Vascular smooth muscle cells (VSMCs) are a major cell type present at intimal thickenings and all stages of an atherosclerotic plaque but with altered phenotypes [1]. The phenotypic switching of VSMCs, which is characterized by reduced myofilament density and contractile protein expression, is a key event during the development of atherosclerosis [2, 3]. Recently, the relative contribution of VSMCs to total foam cell formation has been determined in human atherosclerosis and in the model of mice [4, 5]. However, the mechanism underlying phenotypically switched VSMCs transforming into foam cells remains unclear.
Liver X receptors (LXRs) are members of the nuclear receptor superfamily of ligand-activated transcription factors and are primarily located in the nuclei with or without bound ligand and regulate the expression of genes involved in cholesterol metabolism and inflammation in a tissue-specific manner [6, 7]. The intranuclear concentration of LXRs is maintained by a balance between nuclear import, nuclear export, and nuclear retention. The regulation of this balance provides important regulatory mechanisms for transcription [8]. LXRα-driven expression of the cholesterol efflux transporter ATP-binding cassette transporter (ABCA) 1 is essential for optimal reverse cholesterol transport in peripheral cells, which are associated with the pathogenesis of atherosclerosis [9]. VSMCs switched from contractile to synthetic phenotype metabolize lipids differently to contractile VSMCs, in part through decreased expression of ABCA1, resulting in an increased tendency to transform into foam cells [1, 6], but coordinated regulation of these processes has not been documented.
Smooth muscle (SM) 22α (also known as Transgelin), a differentiated VSMC marker [10], is involved in actin filament assembly and cytoskeletal rearrangements [11], which is required for maintaining the differentiated phenotype of VSMCs [12, 13]. The expression of SM22α has been demonstrated to be downregulated in atherosclerosis and neointima, and further resulted in the depolymerization of the F-actin cytoskeleton, which represents phenotypic changes of VSMCs from the contractile to the synthetic [14, 15]. Loss of SM22α in hypercholesterolemic ApoE-deficient mice results in increased atherosclerotic lesion area and a higher proportion of proliferating SMC-derived plaque cells [16], implying that there is a potential causal relationship between SM22α depletion and atherosclerotic lesion. We and others have demonstrated that disruption of SM22α enhances the inflammatory response in VSMCs [17–19]. Conversely, overexpression of SM22α inhibits proliferation, inflammation, and oxidative stress of VSMC via blockade of different upstream pathways, and prevents neointima hyperplasia and aortic aneurysm formation [20–22]. Furthermore, these physiological and pathological effects of SM22α are mediated by the regulation of actin dynamics to some extent [16, 17]. Recently, the aortic transcriptome profiling suggests that SM22α knockout (Sm22α−/−) mice exhibited the characteristics of pro-atherosclerosis with deregulated nuclear receptors LXR/RXR (retinoid X receptor) and atherosclerosis signaling pathways [20]. Thus, we hypothesized that the protective effects of SM22α on vascular homeostasis may involve the regulation of LXR signaling.
In the current study, we first demonstrated that nuclear accumulation of LXRα is regulated by SM22α-modulated actin dynamics, and altered actin dynamics by SM22α depletion and the resulting inhibition of LXRα nuclear import accelerate the transformation of VSMCs into foam cells and development of atherosclerosis. Monomeric actin (G-actin) from F-actin depolymerization disturbs LXRα nuclear import and retains it in the cytoplasm. The normal LXRα signaling supported by SM22α is a potential target for blockade of VSMC foam cell formation and development of anti-atherosclerosis.
Results
Depletion of SM22α contributes to the development of atherosclerosis in mice
We first took advantage of the published transcriptome analysis obtained on mouse aorta [23], to directly evaluate the sensitivity of Sm22α−/− mice to atherosclerosis. The levels of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) gradually increased and were significantly higher in Sm22α−/− mice than that in wild-type (WT) mice when fed the Paigen diet for 24 weeks with no change of serum triglyceride (TG) levels (Supplementary Fig. 1a–c). The diet significantly increased aortic cholesterol and cholesteryl ester (CE) content in Sm22α−/− mice (Supplementary Fig. 1d). A positive oil red O staining was observed in aortic sinus sections of Sm22α−/− but not of WT mice when fed the Paigen diet, accompanied with diffuse vascular wall thickening (Fig. 1a, b). Moreover, Sm22α−/−Ldlr−/− mice on a Paigen diet displayed an aggravated atherosclerotic lesion compared to Ldlr−/− mice (Fig. 1a and Supplementary Fig. 1e), consistent with the previous finding [16].
Aortic stiffness is believed to be the earliest detectable manifestation of adverse structural and functional changes within the aortic wall [24]. Compared with WT mice, the aortic stiffness parameters, including elastic modulus, stiffness index, and reverse/forward flow ratio, were obviously increased in the outflow tract and aortic arch of Sm22α−/− mice fed Paigen diet, while aortic distensibility was decreased significantly compared with WT mice (Fig. 1c and Supplementary Fig. 1f). HE staining for the aortic sections also showed incomplete vascular structure and fragmentation of elastic fiber (Supplementary Fig. 1e) and a notable increase of fibrosis in the outflow tract and aortic arch of Sm22α−/− mice fed Paigen diet for 12 weeks (Supplementary Fig. 1g, h), which was earlier than the atherosclerotic lesion. The expression of collagen I α (Col1α) increased and elastin (Eln) decreased in the aortic tissues of Sm22α−/− mice (Supplementary Fig. 1i), suggesting that Sm22α−/− mice develop an aortic stiffness phenotype.
Bodipy staining showed that 50 ± 2% of foam cells costained strongly with smooth muscle marker α-actin (ACTA2) (Fig. 1d). Cells expressing both ACTA2 and CD68 that is a marker for macrophages as a percentage of total CD68+ cells were 12 ± 2% (n = 6) in the atherosclerotic lesions of Sm22α−/− mice (Fig. 1d), which was approximately one-fourth of the macrophages, consistent with that observed in the atherosclerotic lesions of ApoE−/− mice and human coronary artery [5]. The expression of LXRα and ABCA1 at mRNA and protein levels decreased in the aortic tissues from Sm22α−/− mice fed with Paigen diet or not, compared with WT mice (Supplementary Fig. 1j, k). Surprisingly, we observed numerous nuclear LXRα-staining negative VSMCs in the aortic sections from Sm22α−/− mice (Fig. 1e), suggesting that LXRα nuclear localization is disturbed. Overall, these data demonstrated that SM22α depletion induces arteriosclerosis via a mechanism that involves the dysfunction of LXRα activity.
Expression and activity of LXRα are abnormal in Sm22α−/− VSMCs
We next mainly examined the effect of SM22α loss on the expression and distribution of LXRs in VSMCs as macrophages did not express SM22α [25]. The expression of LXRα was lower in Sm22α−/− VSMCs than that in WT cells under basic conditions, and no difference in LXRβ expression was observed. T090- and cholesterol-induced LXRα expression was repressed in Sm22α−/− VSMCs compared to WT VSMCs (Fig. 2a and Supplementary Fig. 2a). To further establish the causal relevance of SM22α in the expression of LXRα, WT VSMCs were transfected with the specific siRNA of SM22α and Sm22α−/− VSMCs with Ad-GFP-SM22α. We showed that knockdown of SM22α resulted in reduced expression of LXRα at mRNA and protein levels in WT VSMCs with or without cholesterol loading (Fig. 2b). Conversely, the downregulation of LXRα was significantly reversed by the rescue of SM22α expression in Sm22α−/− VSMCs (Fig. 2c).
As VSMCs with negative nuclear LXRα-staining were found in the aortic sections of Sm22α−/− mice, we next determined whether the subcellular distribution of LXRα is changed in Sm22α−/− VSMCs. We showed that endogenous LXRα was mainly accumulated in the nucleus of WT VSMCs. However, nuclear LXRα was almost little in Sm22α−/− VSMCs, which exhibited diffuse cytoplasmic staining (Fig. 2d), and the ratio of cytoplasmic-/nuclear-LXRα protein markedly increased compared to WT controls (Supplementary Fig. 2b). The rescue of SM22α expression restored endogenous LXRα nuclear localization in Sm22α−/− VSMCs (Fig. 2e), whereas the overexpression of LXRα-GFP was unable to do this, suggesting that LXRα nuclear accumulation is SM22α-dependent and not influenced by LXRα level, and that defect of LXRα nuclear localization further reduces its expression, as LXRα is also a direct target gene of LXRα and enhances its own expression [26].
Activation of LXRα is also able to suppress collagen expression not only promotes transcription of lipid transport and, metabolism genes [27, 28], and VSMCs, as the main origin of extracellular matrix (ECM), are a significant regulator of ECM remodeling and arterial stiffness [29]. We showed that the mRNA level of ABCA1, ABCG1, and Eln was significantly downregulated (Fig. 2f), while the expression of Col1α was significantly elevated in Sm22α−/− VSMCs under basic and cholesterol loading conditions. By comparison, SM22α loss had little effect on the expression of cholesterol intake genes LDL receptor (LDLR) and scavenger receptor class B type I (SR-BI). Cholesterol-induced dynamic upregulation of ABCA1 expression observed from WT cells was missed in Sm22α−/− VSMCs (Fig. 2g), accompanied by increased cholesterol accumulation in a time-dependent manner (Fig. 2h). Reduced ABCA1 expression and increased cholesterol accumulation were verified in VSMCs with knockdown of SM22α (Supplementary Fig. 2c–e). Chromatin immunoprecipitation (ChIP) assay showed that the binding activity of LXRα to the promoter of abca1 and col1α genes was decreased in Sm22α−/− VSMCs compared to WT VSMCs (Fig. 2i, j), in accordance with decreased ABCA1 and increased Col1α expression. Rescue of SM22α expression in Sm22α−/− VSMCs by transduction with Ad-GFP-SM22α increased in binding activity of LXRα to col1α promoter with a reduced Col1α expression (Supplementary Fig. 2f, g). Overall, these data indicate that LXRα transcriptional regulatory activity is repressed in Sm22α−/− VSMCs.
Not only does cholesterol deposits in foam cells at the atherosclerotic plaque, it also regulates cellular mechanics in atherosclerosis progression [30]. Next, the force-curve and Young’s modulus of individual VSMCs were measured by atomic force microscopy (AFM). E-modulus of Sm22α−/− VSMCs was higher and significantly increased in response to cholesterol loading compared with WT cells (Fig. 2k), suggesting that cholesterol accumulation and substrate stiffness induce alternation of the biomechanics of VSMCs. Taken together, these results suggest that SM22α loss contributes to stiffness and foam cell formation of VSMCs.
Nuclear localization and signaling of LXRα are impaired in phenotypically switched VSMCs
SM22α loss is a prominent marker of phenotypic switching of VSMCs [10], and Sm22α−/− VSMCs have the characteristic of synthetic and pro-inflammatory phenotypes [17–19]. To determine whether the dysfunction of the LXRα-ABCA1 axis is common in phenotypically modulated VSMCs, we performed the proteomic analysis of the contractile and synthetic VSMCs and showed that the expression of ABCA1 was markedly reduced in the synthetic VSMCs (Fig. 3a, b and Supplementary Fig. 3a). We validated that the expression of SM22α, ABCA1 and LXRα mRNAs decreased in a time-dependent manner in PDGF-BB-induced VSMCs (Fig. 3c). Notably, LXRα was gradually shifted from the nuclear to the cytoplasm in some VSMCs with extended PDGF-BB stimulation time (Fig. 3d). To determine whether nuclear localization of LXRα is impaired in modulated VSMCs in vivo, we examined VSMCs in the media and the neointima of mice. As expected, LXRα was mainly distributed in the nucleus of the medial VSMCs in the normal artery, whereas LXRα localization was shifted from the nucleus to the cytoplasm and merged with ACTA2 in the neointima VSMCs undergoing phenotypic modulation (Fig. 3e), indicating that LXRα nuclear localization was disturbed in these modulated VSMCs. To further confirm the effect of reduced LXRα-ABCA1 activity on lipid metabolism, the lipid profiles of VSMCs treated with PDGF-BB were assessed by a lipidomic analysis. Comparison of the lipidome between the contractile and synthetic phenotypes showed that CE was significantly increased compared with other lipids (Fig. 3f and Supplementary Fig. 3b), which was a prominent feature of the lipid profiles of synthetic VSMCs (Fig. 3g). Moreover, increased cholesterol deposition was also validated in PDGF-BB-induced VSMCs by ORO staining (Fig. 3h). Overall, these data further suggest that nuclear localization and signaling of LXRα are impaired during phenotypic switching of VSMCs, associated with the depletion of SM22α.
Targeting SM22α supports normal LXRα signaling and ameliorates atherosclerosis
To further identify a potential causative link between SM22α expression and LXRα signaling, we selected an AAV carrying SM22α to perform a gain-of-function study in Sm22α−/− mice fed Paigen diet. As expected, the administration of AAV-SM22α restored SM22α expression in the aortic wall of Sm22α−/− mice accompanied with enhanced aortic GFP signal, indicating a high efficiency of viral transfection (Supplementary Fig. 3c, e). Compared with AAV-GFP mice, the administration of AAV-SM22α significantly reduced Paigen diet-induced aortic stiffness and atherosclerotic lesion (Fig. 3i, j and Supplementary Fig. 3d, e), indicating that AAV-SM22α intervention is effective. qRT-PCR showed that Col1α expression was decreased and the expression of Eln, LXRα and ABCA1 was elevated in the aortic wall of Sm22α−/− mice with AAV-SM22α (Supplementary Fig. 3f), accompanied with reduced expression of MCP-1, MMP2, MMP9, VCAM-1 and ICAM-1 that are downstream of NF-κB, as LXRα has been reported to inhibit NF-κB activity [31]. Importantly, LXRα was mainly accumulated in the nucleus of VSMCs (Fig. 3k), and VSMC marker positive foam cells were reduced in the aortic arch of Sm22α−/− mice with AAV-SM22α (Fig. 3l). Collectively, these findings suggest that SM22α ameliorates atherosclerosis via supporting nuclear localization of LXRα.
Nuclear import of LXRα is regulated by actin dynamics
To elucidate the mechanism underlying cytoplasmic retention of LXRα, nuclear import of LXRα-GFP was measured by fluorescence loss in photobleaching (FLIP) and fluorescence recovery after photobleaching (FRAP) experiments. In WT cells, nuclear import of LXRα-GFP was extremely rapid, being effectively complete within 2 min (Fig. 4a and Supplementary Movie 1) and dramatically delayed and reduced in Sm22α−/− cells (Supplementary Movie 2). LXRα phosphorylation and the formation of a heterodimer with retinoid X receptor (RXR) have been demonstrated to be required for LXRα nuclear accumulation [32, 33]. We showed that SM22α loss did not affect the phosphorylation of LXRα (Supplementary Fig. 4a), and also had no effect on the interaction between LXRα and RXRα (Supplementary Fig. 4b).
To investigate the possible sequestering proteins that retard LXRα nuclear import, we performed affinity purification using an anti-LXRα antibody, and the precipitates were subjected to mass spectrometry analysis. A total of 48 proteins potentially interacting with LXRα was identified (Supplementary Table). Next, we used GO enrichment analysis to cluster and characterize these proteins according to their biological processes (Supplementary Fig. 4c). Ultimately, the actin associated with muscle cell differentiation was selected as a candidate for its reported function in guiding transcriptional factors nuclear transport [34, 35]. As disruption of SM22α promotes actin cytoskeleton remodeling in VSMCs [17, 22], we subsequently compared actin organization between Sm22α−/− and WT cells. Sm22α−/− VSMCs exhibited less fraction of bundled stress fibers (Fig. 4b), and a higher total G-actin and parallel reduced ratio of F-actin to G-actin compared to WT cells (Supplementary Fig. 4d). Moreover, LXRα was mainly distributed in the perinuclear area of the cytoplasm with less F-actin in Sm22α−/− VSMCs (Fig. 4c). To validate whether altered actin organization is associated with impaired nuclear translocation of LXRα, VSMCs were treated with jasplakinolide (JPK) which stabilizes F-actin and cytochalasin-B (CytoB) that inhibits actin polymerization. We showed that LXRα almost entirely remained in the cytoplasm of VSMCs treated by CytoB (Fig. 4d), with a decreased ratio of F-actin to G-actin (Supplementary Fig. 4d), and JPK did not affect the nuclear accumulation of LXRα. CytoB washout restored actin dynamics and distribution of LXRα in the nucleus (Fig. 4d and Supplementary Fig. 4d). Western blot for LXRα expression in the nuclear and cytoplasm fractions showed that LXRα protein was gradually shifted from the nuclear to the cytoplasm during CytoB treatment for different times, with increased cytoplasm/nucleus ratio of LXRα (Fig. 4e). Together, these data for the first time demonstrated that LXRα is a mechanosensitive nuclear receptor and that nuclear translocation of LXRα is regulated by actin dynamics.
G-actin directly interacts with and retains LXRα in the cytoplasm
To test whether LXRα directly interacts with actin in vivo, we performed computational docking analysis for G-actin and LXRα via the ZDOCK server and discovered the highest-scored predicted model of interaction between them (Supplementary Fig. 4e). As LXRα did not colocalize with the F-actin cytoskeleton (Fig. 4c), we used DnaseI to label G-actin and observed that G-actin colocalized with LXRα in the cytoplasm of Sm22α−/− and CytoB-treated VSMCs (Fig. 5a). Next, F-actin and G-actin fractions isolated from WT and Sm22α−/− VSMCs were subjected to co-immunoprecipitation (co-IP) with specific anti-ACTA2 and anti-LXRα antibodies. A specific LXRα band was present in the complex immunoprecipitated by the anti-ACTA2 antibody in the G-actin fraction but not in the F-actin fraction of Sm22α−/− but not WT VSMCs (Fig. 5b). Meanwhile, ACTA2 did not co-immunoprecipitate with LXRβ in both F-actin and G-actin fractions of Sm22α−/− VSMCs (Fig. 5c). Importantly, an atherosclerotic lesion assay using DNaseI and anti-LXRα antibodies revealed a colocalization between endogenous LXRα and G-actin in the aortic wall of Sm22α−/− mice (Fig. 5d). To further validate that increased G-actin level contributes to the retention of LXRα in the cytoplasm, we overexpressed HA-ACTA2 in WT VSMCs and showed that DNaseI-stained G-actin markedly increased (Supplementary Fig. 5a). Importantly, endogenous LXRα redistributed from the nucleus to the cytoplasm and colocalized with ACTA2 in the VSMCs (Fig. 5e), and exogenous LXRα-GFP was so in co-expressed cells. Similar results were observed in HEK-293A cells co-expressing LXRα-GFP and HA-ACTA2, different from the cells expressing LXRα-GFP alone that had nuclear LXRα-GFP fluorescence (Fig. 5f). Thus, G-actin is a novel inhibitor of LXRα nuclear accumulation.
To gain direct insight into G-actin-LXRα interaction in cells, we exploited stochastic optical reconstruction microscopy (STORM) [36], a super-resolution imaging method, to examine the spatial distributions of the two proteins. In WT cells, an obvious much broader peak was observed for the nearest-neighbor distribution of LXRα and G-actin (Fig. 5g). Upon treatment with CytoB, STORM displayed a significant reduction in the nearest-neighbor distance between LXRα and G-actin (Fig. 5h). A quantitatively similar increase in colocalization between LXRα and G-actin was observed using Sm22α−/− VSMCs (Fig. 5i). Such colocalization was abolished by the rescue of SM22α expression (Fig. 5j). Together, these findings suggest that LXRα is recruited by G-actin.
G-actin binding disturbs interaction between LXRα and Importin α
Binding to Importin α that is to serve as an adaptor is the first step in the nuclear transport of nuclear receptors by that link them to Importin β to form a ternary complex in the cytoplasm [37]. We observed that neither CytoB treatment nor loss of SM22α changed Importin α expression (Fig. 5k). Notably, the expression of Importin α in the LXRα-immunoprecipitated complex decreased evidently or even disappeared in Sm22α−/− VSMCs compared to WT cells, which was returned the level to WT cells via the rescue of SM22α expression (Fig. 5k). Similarly, the LXRα-Importin α complex was decreased in CytoB and PDGF-BB-treated WT VSMCs, accompanied with reduced nuclear LXRα expression (Supplementary Fig. 5b), indicating that Importin α-mediated LXRα nuclear import was inhibited by altered actin dynamics, associated with VSMC phenotypes. These results were verified by immunofluorescence staining and confocal analysis (Fig. 5l). Next, we used STORM to examine the spatial relationship of LXRα to Importin α. In WT VSMCs, LXRα colocalized with Importin α, which was reflected by a nearest-neighbor distribution with a sharp peak near the 10−50 nm theoretical resolution limit of STORM (Fig. 5g), whereas disruption of F-actin by CytoB treatment or SM22α knockout completely eliminated this natural colocalizations (Fig. 5h, i), which displayed increased dramatically the nearest-neighbor distribution. The degree of colocalization between LXRα and Importin α was similar to WT cells upon the rescue of SM22α expression (Fig. 5j). This finding was supported by co-immunoprecipitation experiments (Fig. 5m). Taken together, these results suggest that G-actin acts as a molecular shield against LXRα binding to Importin α.
The C-terminal domain mediates the interaction between G-actin and LXRα
To characterize which part of ACTA2 is responsible for LXRα interaction, we then reconstructed the two structural domains of ACTA2 with HA-tagged truncated N-terminus (HA-ACTA2-NT, aa. 1−140) and C-terminal domains (HA-ACTA2-CTD, aa. 141−377) (Supplementary Fig. 6a), and used different truncation derivatives of ACTA2 to gain insight into the location of the interaction. The cells expressing HA-ACTA2-CTD displayed increased LXRα-GFP fluorescence intensity in the cytoplasm and reduced nuclear localization of LXRα-GFP (Fig. 6a) like HA-ACTA2-overexpressed cells (Fig. 5f). Furthermore, the ACTA2-CTD, but not ACTA2-NT, colocalized with LXRα-GFP in the cytoplasm. Similarly, in HEK293A cells co-expressing LXRα-GFP and ACTA2 truncation derivatives, the ACTA2-CTD colocalized with LXRα-GFP in the cytoplasm and abolished nuclear LXRα-GFP, whereas the ACTA2-NT did not influence the nuclear accumulation of LXRα-GFP (Fig. 6b), suggesting that ACTA2-CTD predominantly contributed to this interaction and retarded nuclear import of LXRα.
Because there were no RPEL motifs that bind to actin in LXRα sequence [38], in turn, we constructed the two truncated mutants of LXRα-N-terminus (NT, aa. 1−170) that contained the DNA binding domain and three nuclear localization sequences (NLSs) (NLS1, 2 and 4) and LXRα-C-terminal domains (CTD, aa. 171−445) that included the hinge region, one NLS (NLS3) and the putative ligand-binding domain (Supplementary Fig. 6b) [8, 39], and transfected them into Sm22α−/− VSMCs. We showed that only LXRα-NT was accumulated in the nucleus, and LXRα-CTD, like endogenous LXRα, was also trapped in the cytoplasm of Sm22α−/− cells (Fig. 6c). Similarly, nuclear localization of only LXRα-NT was observed in HEK293A cells co-expressing HA-ACTA2-CTD, whereas LXRα-CTD colocalized with ACTA2-CTD in the cytoplasm (Fig. 6d). Next, peptide pull-down experiments with recombinant purified GST-LXRα, GST-LXRα-NT, and GST-LXRα-CTD revealed that both GST-LXRα and GST-LXRα-CTD bound directly to ACTA2 and ACTA2-CTD rather than ACTA2-NT (Fig. 6e). Thus, LXRα-CTD is the region for ACTA2 recognizing and binding to LXRα. Together, these data suggest that the C-terminal domains mediate the interaction between G-actin and LXRα.
Discussion
In the present study, we showed that the depletion of SM22α dysregulated LXRα signaling and promoted foam cell formation of VSMCs and the development of atherosclerosis. G-actin interacted with LXRα and inhibited its nuclear import, as the complex blocked LXRα binding to Imporin α. SM22α regulated the nuclear localization of LXRα through a mechanism in which F-actin polymerization by SM22α led to dissociation of this complex (Fig. 6f). Using Sm22α−/− and Sm22α−/−Ldlr−/−mice, we provide evidence for a causative role of SM22α loss in LXRα signaling and VSMCs foam cell formation. G-actin was identified as a negative regulator of the LXRα nuclear import and activity.
The disruption of LXRα is believed to be an important factor in the pathological development of atherosclerosis via leading to foam cell formation in macrophages of the arterial wall [9, 40, 41]. Though the expression of LXRα is lower in human VSMCs, limited studies have demonstrated that LXRα can influence proliferation, contractility, apoptosis, and calcification in VSMCs [42]. Moreover, ABCA1 expression is reduced in neointimal VSMCs compared with those isolated from the medial layer [43], more so in advanced relative to early atherosclerosis [44]. In the current study, similar atherosclerotic phenotypes to those of LXRα-deficient mice were observed in Sm22α−/− mice in the context of hypercholesterolemia. The diffuse thickenings of the vascular walls and aortic stiffness existed in Sm22α−/− mice on a Paigen diet for 12 weeks, which are widely considered the most likely precursor of atherosclerotic plaques [1, 45]. Rescue of SM22α expression could alleviate cholesterol overload and displayed anti-atherogenic effects that presented as reduced aortic stiffness and lesion area. Interestingly, we demonstrated that one different aspect from the study on Lxrα−/− mice is that the increased atherosclerosis in Sm22α−/− mice is associated with an inability of VSMCs rather than macrophages to efficiently efflux cholesterol through the LXR pathway. More importantly, the observation that nuclear import of LXRα was impaired in VSMCs of Sm22α−/− mice was removed by the rescue of SM22α expression in vitro and in vivo. Our findings suggest a particularly important role for SM22α in LXRα-mediated cholesterol homeostasis and contractile phenotype in VSMCs especially in the context of hypercholesterolemia and provide evidence that SM22α contributes to the anti-atherogenic effects of LXRα on VSMCs.
De-differentiation, modulation or phenotype switching of VSMCs is characterized by reduced myofilament density and lower expression of contractile proteins [1]. It is known that modulated VSMCs predominate in the thickened arterial intima at atherosclerosis-prone sites prior to the onset of plaque formation and VSMC foam cell formation is resulted from modulated VSMCs engulfing oxidized low-density lipoprotein [46]. In the present study, the proteomic and lipidomic analysis showed that SM22α loss correlated with reduced LXRα-ABCA1 expression and increased cholesteryl ester in phenotypically modulated VSMCs. We validated that LXRα was redistributed from the nuclear to the cytoplasm in VSMCs upon PDGF-BB stimulation and in the neointima VSMCs and that LXRα colocalized with G-actin in the cytoplasm, suggesting that LXRα nuclear localization is regulated by actin dynamics and is impaired as a result of VSMC phenotypic switching. Our findings indicated that SM22α loss-mediated aberrant actin-LXRα signaling pathway guides modulated VSMCs to ultimately transform into foam cells. Our results support the idea that lipid metabolism programming is a critical event in phenotypic switching of VSMCs and that SM22α activates the LXRα-ABCA1 axis to maintain lipid homeostasis through the modulation of cytoskeletal actin polymerization.
We acknowledge several limitations of this study. First, SM22α is not only expressed in SMCs but also expressed in other lineages, such as cardiomyocytes during development and myeloid cells [47]. Therefore, using inducible SMC-specific SM22α knockout mice are warranted to accurately define a more definitive causal relationship between SM22α expression in VSMCs and their contribution to atherosclerotic lesion formation. Second, polymerization and depolymerization in live cells are regulated by actin-binding proteins. It needs further to explore whether and how other actin-binding proteins are involved in the regulation of LXRα signaling and cholesterol metabolism. Finally, given the involvement of the actin cytoskeleton remodeling in phenotypic switching of VSMC, it will be important to determine how these and similar pathways of aberrant actin-to-LXRα crosstalking can be intervened by the development of therapeutic agents.
Supplementary information
Acknowledgements
We thank Dr. Mingming Gao at Lipid Metabolism Laboratory for technical support on animal experiments; Dr. Chang Wang and Huan Chen at Human Anatomy Department for technical support with FLIP and FRAP experiments; Dr. Ce Liang at Pharmacology Department for technical support with STORM experiments; Dr. Hongyuan Yang at School of Biotechnology and Biomolecular Sciences of Australia University of New South Wales for discussions, and comments on the data.
Author contributions
MH initiated the project and designed the paper. D-DZ, YS, and PK performed most of the experiments and/or analyzed data. Y-KG, XX, X-WW, and Y-LL assisted in animal experiments. LW, Y-QD, and FZ assisted in in vitro experiments and histological analyses. PK and D-DZ generated the illustrations. MH wrote the manuscript and edited the manuscript. All authors read and approved the final manuscript.
Funding
This work was supported by the National Natural Science Foundation of China, including 91739301, 91849102, and 31872788. This work was funded by the Key Natural Science Foundation Projects of Hebei Province H2019206028, Natural Science Foundation of Hebei Province H2021206006 and H2021423047, and Natural Science Youth Fund of Hebei Province Education Department QN2020167, by the administrative departments of science and technology at the Hebei Medical University with funding from the Project Supporting Fund established and appropriated by the Hebei Medical University Budget Committee.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Edited by Professor Anastasis Stephanou
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Dan-Dan Zhang, Yu Song, Peng Kong.
Change history
11/10/2021
A Correction to this paper has been published: 10.1038/s41419-021-04360-w
Supplementary information
The online version contains supplementary material available at 10.1038/s41419-021-04239-w.
References
- 1.Basatemur GL, Jrgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol. 2019;16:727–44. doi: 10.1038/s41569-019-0227-9. [DOI] [PubMed] [Google Scholar]
- 2.Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:503–16. doi: 10.1016/s0092-8674(01)00238-0. [DOI] [PubMed] [Google Scholar]
- 3.Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25. doi: 10.1038/nature10146. [DOI] [PubMed] [Google Scholar]
- 4.Allahverdian S, Chehroudi AC, Mcmanus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014;129:1551–9. doi: 10.1161/CIRCULATIONAHA.113.005015. [DOI] [PubMed] [Google Scholar]
- 5.Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015;21:628–37. doi: 10.1038/nm.3866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454:470–7. doi: 10.1038/nature07202. [DOI] [PubMed] [Google Scholar]
- 7.Ferber Dan. Possible new way to lower cholesterol. Science. 2000;289:1446–7. doi: 10.1126/science.289.5484.1446. [DOI] [PubMed] [Google Scholar]
- 8.Prufer K, Boudreaux J. Nuclear localization of liver X receptor alpha and beta is differentially regulated. J Cell Biochem. 2007;100:69–85. doi: 10.1002/jcb.21006. [DOI] [PubMed] [Google Scholar]
- 9.Schuster GU, Parini P, Wang L, Alberti S, Steffensen KR, Hansson GK, et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation. 2002;106:1147–53. doi: 10.1161/01.cir.0000026802.79202.96. [DOI] [PubMed] [Google Scholar]
- 10.Wirka RC, Wagh D, Paik DT, Pjanic M, Nguyen T, Miller CL, et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. Nat Med. 2019;25:1280–9. doi: 10.1038/s41591-019-0512-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, Lu MM, et al. Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol. 2001;21:1336–44. doi: 10.1128/MCB.2001.21.4.1336-1344.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Fu Y, Liu HW, Forsythe SM, Kogut P, McConville JF, Halayko AJ, et al. Mutagenesis analysis of human SM22: characterization of actin binding. J Appl Physiol. 2000;89:1985–90. doi: 10.1152/jappl.2000.89.5.1985. [DOI] [PubMed] [Google Scholar]
- 13.Han M, Dong LH, Zheng B, Shi JH, Wen JK, Cheng Y. Smooth muscle 22 alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling. Life Sci. 2009;84:394–401. doi: 10.1016/j.lfs.2008.11.017. [DOI] [PubMed] [Google Scholar]
- 14.Wamhoff BR, Hoofnagle MH, Burns A, Sinha S, McDonald OG, Owens GK. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res. 2004;95:981–8. doi: 10.1161/01.RES.0000147961.09840.fb. [DOI] [PubMed] [Google Scholar]
- 15.Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, Schaller M, et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res. 2014;115:662–7. doi: 10.1161/CIRCRESAHA.115.304634. [DOI] [PubMed] [Google Scholar]
- 16.Feil S, Hofmann F, Feil R. SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. Circ Res. 2004;94:863–5. doi: 10.1161/01.RES.0000126417.38728.F6. [DOI] [PubMed] [Google Scholar]
- 17.Shen J, Yang M, Ju D, Jiang H, Zheng JP, Xu Z, et al. Disruption of SM22 promotes inflammation after artery injury via nuclear factor kappaB activation. Circ Res. 2010;106:1351–62. doi: 10.1161/CIRCRESAHA.109.213900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Shu YN, Zhang F, Bi W, Dong LH, Zhang DD, Chen R, et al. SM22α inhibits vascular inflammation via stabilization of IκBα in vascular smooth muscle cells. J Mol Cell Cardiol. 2015;84:191–9. doi: 10.1016/j.yjmcc.2015.04.020. [DOI] [PubMed] [Google Scholar]
- 19.Shu YN, Dong LH, Li H, Pei QQ, Miao SB, Zhang F, et al. CKII-SIRT1-SM22α loop evokes a self-limited inflammatory response in vascular smooth muscle cells. Cardiovasc Res. 2017;113:1198–207. doi: 10.1093/cvr/cvx048. [DOI] [PubMed] [Google Scholar]
- 20.Dong LH, Wen JK, Liu G, McNutt MA, Miao SB, Gao R, et al. Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia. Arterioscler Thromb Vasc Biol. 2010;30:683–91. doi: 10.1161/ATVBAHA.109.200501. [DOI] [PubMed] [Google Scholar]
- 21.Zhong L, He X, Si X, Wang H, Li B, Hu Y, et al. SM22α (smooth muscle 22α) prevents aortic aneurysm formation by inhibiting smooth muscle cell phenotypic switching through suppressing reactive oxygen species/NF-κB (nuclear factor-κB) Arterioscler Thromb Vasc Biol. 2019;39:10–25. doi: 10.1161/ATVBAHA.118.311917. [DOI] [PubMed] [Google Scholar]
- 22.Lv P, Miao SB, Shu YN, Dong LH, Liu G, Xie XL, et al. Phosphorylation of smooth muscle 22α facilitates angiotensin II-induced ROS production via activation of the PKCδ-P47phox axis through release of PKCδ and actin dynamics and is associated with hypertrophy and hyperplasia of vascular smooth muscle cells in vitro and in vivo. Circ Res. 2012;111:697–707. doi: 10.1161/CIRCRESAHA.112.272013. [DOI] [PubMed] [Google Scholar]
- 23.Chen R, Zhang F, Song L, Shu Y, Lin Y, Dong L, et al. Transcriptome profiling reveals that the SM22α-regulated molecular pathways contribute to vascular pathology. J Mol Cell Cardiol. 2014;72:263–72. doi: 10.1016/j.yjmcc.2014.04.003. [DOI] [PubMed] [Google Scholar]
- 24.Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011;57:1511–22. doi: 10.1016/j.jacc.2010.12.017. [DOI] [PubMed] [Google Scholar]
- 25.Lv P, Yin YJ, Kong P, Cao L, Xi H, Wang N, et al. SM22alpha loss contributes to apoptosis of vascular smooth muscle cells via macrophage-derived circRasGEF1B. Oxid Med Cell Longev. 2021;2021:5564884. doi: 10.1155/2021/5564884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Whitney KD, Watson MA, Goodwin B, Galardi CM, Maglich JM, Wilson JG, et al. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J Biol Chem. 2001;276:43509–15. doi: 10.1074/jbc.M106155200. [DOI] [PubMed] [Google Scholar]
- 27.Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H, et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology. 2011;140:1052–62. doi: 10.1053/j.gastro.2010.11.053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Hamilton JP, Koganti L, Muchenditsi A, Pendyala VS, Huso D, Hankin J, et al. Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B(-/-) (Wilson disease) mice. Hepatology. 2016;63:1828–41. doi: 10.1002/hep.28406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767–801. doi: 10.1152/physrev.00041.2003. [DOI] [PubMed] [Google Scholar]
- 30.Sanyour HJ, Li N, Rickel AP. Statin-mediated cholesterol depletion exerts coordinated effects on the alterations in rat vascular smooth muscle cell biomechanics and migration. J Physiol. 2020;598:1505–1522. doi: 10.1113/JP279528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wu S, Yin R, Ernest R, Li Y, Zhelyabovska O, Luo J, et al. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-κB signalling. Cardiovasc Res. 2009;84:119–26. doi: 10.1093/cvr/cvp180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 2003;15:355–66. doi: 10.1016/s0898-6568(02)00115-8. [DOI] [PubMed] [Google Scholar]
- 33.Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012;13:213–24. doi: 10.1038/nrm3312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Saha T, Guha D, Manna A, Panda AK, Bhat J, Chatterjee S, et al. G-actin guides p53 nuclear transport: potential contribution of monomeric actin in altered localization of mutant p53. Sci Rep. 2016;6:32626. doi: 10.1038/srep32626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Ho CY, Jaalouk DE, Vartiainen MK, Lammerding J. Lamin A/C and emerin regulate MKL1-SRF activity by modulating actin dynamics. Nature. 2013;497:507–11. doi: 10.1038/nature12105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Zhou R, Han B, Xia C. Membrane-associated periodic skeleton is a signaling platform for RTK transactivation in neurons. Science. 2019;365:929–34. doi: 10.1126/science.aaw5937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Goldfarb DS, Corbett AH, Mason DA, Harreman MT, Adam SA. Importin alpha: a multipurpose nuclear-transport receptor. Trends Cell Biol. 2004;14:505–14. doi: 10.1016/j.tcb.2004.07.016. [DOI] [PubMed] [Google Scholar]
- 38.Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell. 2003;113:329–42. doi: 10.1016/s0092-8674(03)00278-2. [DOI] [PubMed] [Google Scholar]
- 39.Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell. 2007;28:91–106. doi: 10.1016/j.molcel.2007.07.032. [DOI] [PubMed] [Google Scholar]
- 40.Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA. 2002;99:11896–901. doi: 10.1073/pnas.182199799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213–9. doi: 10.1038/nm820. [DOI] [PubMed] [Google Scholar]
- 42.Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:1513–8. doi: 10.1161/ATVBAHA.109.191197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Choi HY, Rahmani M, Wong BW, Allahverdian S, McManus BM, Pickering JG, et al. ATP-binding cassette transporter A1 expression and apolipoprotein A-I binding are impaired in intima-type arterial smooth muscle cells. Circulation. 2009;119:3223–31. doi: 10.1161/CIRCULATIONAHA.108.841130. [DOI] [PubMed] [Google Scholar]
- 44.Bradley MN, Hong C, Chen M, Joseph SB, Wilpitz DC, Wang X, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest. 2007;117:2337–46. doi: 10.1172/JCI31909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–75. doi: 10.1161/01.atv.20.5.1262. [DOI] [PubMed] [Google Scholar]
- 46.Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, Martinez FO, et al. Cholesterol loading reprograms the microRNA-143/145–myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler Thromb Vasc Biol. 2015;35:535–46. doi: 10.1161/ATVBAHA.114.304029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Raja C, Fatima ZS, Ana CC, Diane SK, Daniel MG, Kathleen AM. Promoters to study vascular smooth muscle: mistaken identity? Arterioscler Thromb Vasc Biol. 2019;39:603–12. doi: 10.1161/ATVBAHA.119.312449. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.